Back to Search
KATHERINE MERKLE, DO
DO
Family Medicine Physician
NPI: 1134415292IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
DO176533(OR)
CMS Specialties
PrimaryUNDEFINED PHYSICIAN TYPE (SPECIFY)
Additional
FAMILY PRACTICEOSTEOPATHIC MANIPULATIVE MEDICINE
Education
OTHER
Class of 2011
Research & Publications (20)
ERP responses differentiate inverted but not upright face processing in adults with ASD.
PMID 19454620·Soc Cogn Affect Neurosci·2012
8-other
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
PMID 19652068·J Clin Oncol·2009
3-trial
An investigation of the relationship between fMRI and ERP source localized measurements of brain activity during face processing.
PMID 19322649·Brain Topogr·2009
4-observational
Brief report: face configuration accuracy and processing speed among adults with high-functioning autism spectrum disorders.
PMID 18751880·J Autism Dev Disord·2009
8-other
A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours.
PMID 17486132·Br J Cancer·2007
3-trial
A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
PMID 17414628·Anticancer Drugs·2007
3-trial
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO).
PMID 16402269·J Cancer Res Clin Oncol·2006
3-trial
Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy.
PMID 16292542·J Cancer Res Clin Oncol·2006
3-trial
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC.
PMID 16096436·Anticancer Drugs·2005
3-trial
Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma.
PMID 15845750·Drug Metab Dispos·2005
8-other
Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis.
PMID 15369386·J Med Chem·2004
7-preclinical
Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative.
PMID 15357983·Bioorg Med Chem Lett·2004
7-preclinical
Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis.
PMID 14561098·J Med Chem·2003
7-preclinical
High-performance liquid chromatography-atmospheric pressure photoionization/tandem mass spectrometric analysis for small molecules in plasma.
PMID 12964760·Anal Chem·2003
4-observational
Zirconia-based column high-performance liquid chromatography/atmospheric pressure photoionization tandem mass spectrometric analyses of drug molecules in rat plasma.
PMID 12872283·Rapid Commun Mass Spectrom·2003
7-preclinical
Non-peptide alphavbeta3 antagonists. Part 6: design and synthesis of alphavbeta3 antagonists containing a pyridone or pyrazinone central scaffold.
PMID 12729670·Bioorg Med Chem Lett·2003
8-other
Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics.
PMID 12161158·Bioorg Med Chem Lett·2002
7-preclinical
Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine.
PMID 11862482·J Cancer Res Clin Oncol·2002
5-case
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements.
PMID 11738567·Bioorg Med Chem Lett·2002
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 534 PLEASANT VIEW WAY NW STE 100
ALBANY, OR 97321 - Phone
- (541) 812-5656
Quick Facts
- NPI
- 1134415292
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 15
- Publications
- 20
Are you this provider?
Claim Your Profile